Ambeed.cn

首页 / / / / Madecassic acid/羟基积雪草酸

Madecassic acid/羟基积雪草酸 {[allProObj[0].p_purity_real_show]}

货号:A354620 同义名: Brahmic Acid; NSC 88135

Madecassic acid是一种从积雪草(Centella asiatica)草药中分离并纯化的天然产物,具有抗炎作用,通过抑制 iNOS、COX-2、TNF-alpha、IL-1beta 和 IL-6,以及下调 NF-kappaB 激活来实现,表现出对 RAW 264.7 巨噬细胞的抗炎作用。

Madecassic acid/羟基积雪草酸 化学结构 CAS号:18449-41-7
Madecassic acid/羟基积雪草酸 化学结构
CAS号:18449-41-7
Madecassic acid/羟基积雪草酸 3D分子结构
CAS号:18449-41-7
Madecassic acid/羟基积雪草酸 化学结构 CAS号:18449-41-7
Madecassic acid/羟基积雪草酸 3D分子结构 CAS号:18449-41-7
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

Madecassic acid/羟基积雪草酸 纯度/质量文件 产品仅供科研

货号:A354620 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]
Cell, 2025. Ambeed. [ A122167 ]
Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]
Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]
Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]
更多 >
产品名称 eNOS iNOS nNOS 其他靶点 纯度
1400W 2HCl +

eNOS, Ki: 50 μM

++++

iNOS, Kd: <7 nM

++

nNOS, Ki: 2 μM

99%+
H-Arg(NO2)-OMe·HCl +++

eNOS, Ki: 39 nM

++

iNOS, Ki: 4.4 μM

+++

nNOS, Ki: 15 nM

98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。
产品名称 NF-κB 其他靶点 纯度
Ammonium pyrrolidine-1-carbodithioate 98%
QNZ ++++

NF-κB, IC50: 11 nM

99%+
Sodium 4-Aminosalicylate Dihydrate 98%
Sodium Salicylate 95%
Parthenolide p53 97% HPLC
JSH-23 +

NF-κB, IC50: 7.1 μM

98%
Phenethyl caffeate 98%
Andrographolide 98+%
Curcumin Nrf2,HDAC 98%
SC75741 +++

NF-κB, EC50: 200 nM

99%+
CBL0137 HCl ++

NF-κB, EC50: 0.47 μM

p53 99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。
产品名称 COX COX-1 COX-2 其他靶点 纯度
Piroxicam 98%
Salicylic acid 98%
Phenacetin 98%
Etodolac 99%
Flunixin meglumine 98%
Ibuprofen L-lysine 98%
Nabumetone 98%
Acemetacin 98%
Diflunisal 98%
Pranoprofen 98%
Ampiroxicam 98%
Meloxicam 98%
Sulindac 98%
Ketoprofen 98%
Mefenamic Acid 95%
Bromfenac sodium 98%
Oxaprozin 99%
Aspirin 99%
Nepafenac 98%
Zaltoprofen 99%
Salicin 98%
Suprofen 99%+
Xanthohumol 99%
Parecoxib 98%
Tolfenamic Acid +++

COX-2, IC50: 0.2 μM

98%
Etoricoxib 99%
Niflumic Acid 98%
Valdecoxib ++++

COX-2, IC50: 5 nM

99+%
Ibuprofen +

COX-1, IC50: 13 μM

+

COX-2, IC50: 370 μM

98%
Indomethacin ++

COX1, IC50: 0.28 μM

+

COX-2, IC50: 14 μM

97%
Lornoxicam ++++

COX-1, IC50: 5 nM

++++

COX-2, IC50: 8 nM

98%
Meclofenamic acid sodium ++++

COX-1, IC50: 40 nM

+++

COX-2, IC50: 50 nM

99%
Asaraldehyde 98%
Naproxen +

COX-1, IC50: 8.7 μM

+

COX-2, IC50: 5.2 μM

98%
Diclofenac Sodium Salt +++

COX-1, IC50: 60 nM

+++

COX-2, IC50: 200 nM

98%
NS-398 ++

COX-2, IC50: 3.8 μM

95%
Amfenac Sodium Hydrate ++

COX-1, IC50: 250 nM

+++

COX-2, IC50: 150 nM

98%+
Nimesulide +

COX-2, IC50: 26 μM

98%
Lumiracoxib ++

COX-1, Ki: 3 μM

+++

COX-2, Ki: 60 nM

98%
Rutaecarpine 95%
Celecoxib ++++

COX-2, IC50: 40 nM

98%
Carprofen ++++

canine COX2, IC50: 30 nM

98%
Ketorolac ++

COX-1 (human), IC50: 1.23 μM

++

COX-2 (human), IC50: 3.50 μM

98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

Madecassic acid/羟基积雪草酸 生物活性

描述 Madecassic acid, a natural product isolated and purified from the herbs of Centella asiatica (L.) Urban, has anti-inflammatory properties by iNOS, COX-2, TNF-alpha, IL-1beta, and IL-6 inhibition via the downregulation of NF-kappaB activation in RAW 264.7 macrophage cells.

Madecassic acid/羟基积雪草酸 细胞实验

Cell Line
Concentration Treated Time Description References
Escherichia coli 250 µg/mL Inhibit the growth of Escherichia coli Molecules. 2023 Feb 16;28(4):1895
A431 cells 20 μM 24 hours MA inhibited tumor cell proliferation, migration and invasion, and enhanced the anticancer effect of DOX. Int J Biol Sci. 2024 Oct 7;20(14):5396-5414
HepG2 cells 20 μM 24 hours MA inhibited tumor cell proliferation, migration and invasion, and enhanced the anticancer effect of DOX. Int J Biol Sci. 2024 Oct 7;20(14):5396-5414
MCF-7 cells 20 μM 24 hours MA inhibited tumor cell proliferation, migration and invasion, and enhanced the anticancer effect of DOX. Int J Biol Sci. 2024 Oct 7;20(14):5396-5414
NMVMs 5 μM 24 hours MA pretreatment attenuated the DOX-induced decrease in the mitochondrial membrane potential, reduced mitochondrial fission, and maintained the number and morphology of the mitochondria. Int J Biol Sci. 2024 Oct 7;20(14):5396-5414
H9c2 cells 5 μM 24 hours MA pretreatment significantly attenuated DOX-induced cardiomyocyte injury and cell death, inhibited ROS accumulation and MDA production. Int J Biol Sci. 2024 Oct 7;20(14):5396-5414
γδT17 cells 1, 3, 10 μM 72 hours Inhibited the activation of γδT17 cells and reduced IL-17A expression Cell Death Dis. 2020 Sep 14;11(9):752
RAW264.7 macrophages 10 µM 18 hours To evaluate the protective effect of madecassic acid against LPS-induced oxidative stress. Results showed that madecassic acid significantly reduced NO, TNF-α, and IL-6 production. Antioxidants (Basel). 2024 Apr 18;13(4):483
EA.hy926 endothelial cells 2.5 µM 2 hours To evaluate the protective effect of madecassic acid against H2O2-induced endothelial cell damage. Results showed that madecassic acid significantly increased cell viability, reduced ROS production, and restored GSH levels. Antioxidants (Basel). 2024 Apr 18;13(4):483
HepG2 hepatocytes 5 µM 24 hours To evaluate the protective effect of madecassic acid against TBHP-induced hepatocyte damage. Results showed that madecassic acid significantly increased cell viability, reduced ROS production, and decreased ALT and AST levels. Antioxidants (Basel). 2024 Apr 18;13(4):483
Hs68 human skin fibroblasts 10 µM 24 hours To evaluate the protective effect of madecassic acid against UVB-induced oxidative stress. Results showed that madecassic acid significantly increased cell viability, reduced ROS and MDA production, and restored GSH levels. Antioxidants (Basel). 2024 Apr 18;13(4):483
Bacillus megaterium 62.5 µg/mL Inhibit the growth of Bacillus megaterium Molecules. 2023 Feb 16;28(4):1895
Bacillus subtilis 62.5 µg/mL Inhibit the growth of Bacillus subtilis Molecules. 2023 Feb 16;28(4):1895
Pseudomonas aeruginosa 125 µg/mL Inhibit the growth of Pseudomonas aeruginosa Molecules. 2023 Feb 16;28(4):1895
NIH 3T3 (non-malignant fibroblasts) >30 µM 72 hours Evaluation of cytotoxicity, results showed low cytotoxicity Int J Mol Sci. 2022 Apr 14;23(8):4362
A2780 (ovarian carcinoma) >30 µM 72 hours Evaluation of cytotoxicity, results showed low cytotoxicity Int J Mol Sci. 2022 Apr 14;23(8):4362
MCF7 (breast adenocarcinoma) >30 µM 72 hours Evaluation of cytotoxicity, results showed low cytotoxicity Int J Mol Sci. 2022 Apr 14;23(8):4362
HT29 (colorectal carcinoma) >30 µM 72 hours Evaluation of cytotoxicity, results showed low cytotoxicity Int J Mol Sci. 2022 Apr 14;23(8):4362
A375 (melanoma) >30 µM 72 hours Evaluation of cytotoxicity, results showed low cytotoxicity Int J Mol Sci. 2022 Apr 14;23(8):4362
IL-1β-induced rat primary chondrocytes 10 µM 48 hours MA protected chondrocytes against ECM degradation by upregulating collagen-II and ACAN expression and downregulating MMP-3 and MMP-13 expression. Drug Des Devel Ther. 2022 Nov 1;16:3793-3804
Rat primary chondrocytes 10 µM 48 hours Assessed the effect of MA on chondrocyte viability, finding that 10 µM MA significantly increased chondrocyte viability. Drug Des Devel Ther. 2022 Nov 1;16:3793-3804
Methicillin-resistant Staphylococcus aureus 62.5 µg/mL Inhibit the growth of Methicillin-resistant Staphylococcus aureus Molecules. 2023 Feb 16;28(4):1895
Staphylococcus aureus 31.25 µg/mL 28 hours Inhibit the growth of Staphylococcus aureus Molecules. 2023 Feb 16;28(4):1895
human liver microsomes 0.12 µM Evaluation of reversible inhibition of CYP2C9 by CAW-R61J, IC50 of 330 mg/ml Drug Metab Dispos. 2020 Oct;48(10):1053-1063
EL-4 mouse lymphoma cells 1, 3, 10 μM 24 hours Madecassic acid promoted the expression of PPARγ-responsive genes CD36 and LPL, indicating its role as a PPARγ agonist. Cell Death Dis. 2017 Mar 30;8(3):e2723
Mouse CD4+ T cells 3, 10 μM 4 days Madecassic acid reduced the percentage of CD4+IL-17+ T cells and increased the percentage of CD4+Foxp3+ T cells under Th17-polarizing conditions, indicating it promoted the shift of Th17 toward Treg cells. Cell Death Dis. 2017 Mar 30;8(3):e2723

Madecassic acid/羟基积雪草酸 动物实验

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J male mice DOX-induced acute heart failure mouse model Gavage 25 mg/kg/day Daily for 12 days MA pretreatment significantly attenuated DOX-induced myocardial injury, improved cardiac function, and inhibited myocardial fibrosis and inflammatory response. Int J Biol Sci. 2024 Oct 7;20(14):5396-5414
Female C57BL/6 mice DSS-induced colitis model Oral 25 mg/kg/day Once daily for 10 days Reduced the number of γδT17 cells and attenuated colon inflammation Cell Death Dis. 2020 Sep 14;11(9):752
Sprague-Dawley rats Oral 100 mg/kg Single dose Improved bioavailability Int J Nanomedicine. 2023 May 8;18:2345-2358
Balb/cA mice Diabetic mice model Dietary intake 0.05% or 0.1% Six weeks Improved glycemic control, lowered lipid accumulation, attenuated oxidative and inflammatory stress Nutrients. 2015 Dec 2;7(12):10065-75
Sprague-Dawley rats OA model induced by anterior cruciate ligament transection (ACLT) Intra-articular injection 1 mg/kg Daily for one week, then once every three days for three weeks MA inhibited cartilage matrix degradation and delayed cartilage surface degeneration, slowing OA progression. Drug Des Devel Ther. 2022 Nov 1;16:3793-3804
C57BL/6 mice DSS-induced colitis model Oral 12.5, 25 mg/kg Consecutive 10 days Madecassic acid alleviated DSS-induced colitis in mice by restoring the Th17/Treg balance, decreasing the percentage of Th17 cells and increasing the percentage of Treg cells. Cell Death Dis. 2017 Mar 30;8(3):e2723
ICR mice Bleomycin-induced pulmonary fibrosis model Oral 10, 20 mg/kg Once daily for 21 days To evaluate the effect of madecassic acid on bleomycin-induced pulmonary fibrosis. Results showed that madecassic acid had no significant effect on pulmonary fibrosis. Br J Pharmacol. 2016 Apr;173(7):1219-35

Madecassic acid/羟基积雪草酸 参考文献

[1]Xia B, Bai L, et al. Structural analysis of metabolites of asiatic acid and its analogue madecassic acid in zebrafish using LC/IT-MSn. Molecules. 2015 Feb 12;20(2):3001-19.

[2]Wang T, Leng DD, et al. A LC-ESI-MS method for the simultaneous determination of madecassoside and its metabolite madecassic acid in rat plasma: comparison pharmacokinetics in normal and collagen-induced arthritic rats. Chin J Nat Med. 2014 Dec;12(12):943-51.

Madecassic acid/羟基积雪草酸 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.98mL

0.40mL

0.20mL

9.91mL

1.98mL

0.99mL

19.81mL

3.96mL

1.98mL

Madecassic acid/羟基积雪草酸 技术信息

CAS号18449-41-7
分子式C30H48O6
分子量 504.7
SMILES Code C[C@@]1(CO)[C@@H](O)[C@H](O)C[C@]2(C)[C@@]3([H])CC=C4[C@]5([H])[C@@H](C)[C@H](C)CC[C@@](C(O)=O)5CC[C@](C)4[C@@](C)3C[C@@H](O)[C@@]12[H]
MDL No. MFCD11559128
别名 Brahmic Acid; NSC 88135
运输蓝冰
存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Sealed in dry, 2-8°C

溶解方案

DMSO: 60 mg/mL(118.88 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
方案 一
方案 二
方案 三
AmBeed 相关网站 AmBeed.cn AmBeed.com
AmBeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    AmBeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。